Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064389 | 0.82 | TLR8 (0.37) | TLR8 | |
| SCHEMBL22613548 | 0.81 | ALOX15 (0.33) | TLR8 | |
| SCHEMBL15921771 | 0.78 | TLR8 (0.31) | TLR8 | |
| SCHEMBL4738607 | 0.77 | TAAR1 (0.35) | TLR8 | |
| SCHEMBL23162752 | 0.76 | PTGS2 (0.34) | TLR8 | |
| SCHEMBL23162741 | 0.76 | — | — | |
| SCHEMBL109668 | 0.75 | CYP2D6 (0.34) | — | |
| SCHEMBL30641254 | 0.73 | PTGER1 (0.34) | — | |
| SCHEMBL9899998 | 0.72 | TLR8 (0.35) | TLR8 | |
| SCHEMBL8878787 | 0.72 | RECQL (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDRENS HOSPITAL MED CT (US) | 2025-05-15 | — | — | US | disclosed |
| CN-118613480-A | Polycyclic IRAK and FLT3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024163764-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4377315-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023009833-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022231242-A1 | INDAZOLE COMPOUND HAVING LRRK2 INHIBITORY ACTIVITY | 주식회사 스탠다임 | 2022-11-03 | — | — | WO | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| WO-2013159064-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-1442036-B1 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1442036-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6727254-B2 | 8-(BIS-(PHENYL) METHYL)-3-HETEROARYL-8-AZABICYCLO-(3.2.1)OCTAN-3-OLS AND DERIVATIVES, USEFUL IN TREATING PAIN, ANXIETY, COUGH, ASTHMA, DEPRESION AND ALCOHOL ABUSE | SCHERING CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003039469-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TLR8 2377/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TLR8 2377/4885 |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OPRK1 | TLR8 1413/4885 |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK3 | TLR8 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.